Annovis Bio, Inc.
ANVS
$1.24
-$0.07-5.00%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 113.65% | -6.25% | -44.99% | -32.64% | -43.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.25% | 185.10% | 44.12% | 69.45% | -19.21% |
| Operating Income | -129.25% | -185.10% | -44.12% | -69.45% | 19.21% |
| Income Before Tax | -138.27% | -217.97% | -67.69% | 42.53% | -23.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -138.27% | -217.97% | -67.69% | 42.53% | -23.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.27% | -217.97% | -67.69% | 42.53% | -23.90% |
| EBIT | -129.25% | -185.10% | -44.12% | -69.45% | 19.21% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -23.75% | -98.99% | 9.55% | 62.13% | 28.11% |
| Normalized Basic EPS | -23.76% | -97.93% | 9.56% | 62.12% | 28.11% |
| EPS Diluted | -25.00% | -97.56% | 19.53% | 62.01% | 27.93% |
| Normalized Diluted EPS | -23.76% | -97.93% | 9.56% | 62.12% | 28.11% |
| Average Basic Shares Outstanding | 92.54% | 59.76% | 85.43% | 51.71% | 72.33% |
| Average Diluted Shares Outstanding | 92.54% | 59.76% | 85.43% | 51.71% | 72.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |